|
|
|
연간정보 서비스
The Outlook for Pharmaceuticals in Central & Eastern Europe
|
Abstract
Description
The pharmaceutical market of Central & Eastern Europe is estimated at US$63.6 billion at retail prices in 2011; it is expected to reach US$104.2 billion by 2016. The market is expected to expand by a moderate CAGR in US dollar terms between 2011 and 2016, as the region's economies recover from the global economic crisis.
Dominance of generic medicines
Generic medicines represent around half of the total CEE pharmaceutical market in value terms and almost three quarters in volume terms. Generics have retained their strong position in the region due to the demand for affordable drugs and the fact that some governments favour generics when selecting products for reimbursement, as they are usually cheaper than imported products and help to keep costs down. Although rising incomes have led to increased sales of branded products, recent financial difficulties are likely to have forced patients towards purchasing cheaper generics.
Central and Eastern Europe is home to a large number of generic companies, including Krka, Gedeon Richter, Polpharma and Zentiva, which have traditionally focused on the production of generics. Pharmstandard, Russia's leading generic company, has a small number of original drugs in its portfolio, but many companies lack the funding that is required for extensive R&D. Branded generics are particularly common in Central and Eastern Europe, especially in Russia, due to the tradition of self-medication which has encouraged companies to produce pharmaceuticals with recognisable names and the erroneous belief that pure generics are unsafe.
Different IP protection levels
Much of the pharmaceutical legislation within the region has been harmonised with that of the EU. However, the level of IP protection remains an international concern. Problems that are commonly raised include a lack of transparency in IP procedures and the lack of effective enforcement.
Health Expenditure
The countries of Central & Eastern Europe are projected to spend an estimated US$335.9 billion on healthcare in 2016, equal to 6.8% of GDP. At present, only 39.6% of spending in the region is private, but over 87.0% of this is composed of out-of-pocket payments. Several countries in the region are taking steps to reduce the growth of health expenditure, by passing on a greater proportion of costs to patients, and in some cases to pharmaceutical companies. For instance, in Poland, new legislation coming into force in January 2012 will limit drug reimbursement expenditure to 17% of total public healthcare spending, introduce fixed retail prices for reimbursed medicines and force pharmaceutical companies to cover 50% of any reimbursement overspend.
In Hungary, drug manufacturers have been required to contribute a percentage of their turnover to the Health Insurance Fund since 2004. Additionally, the Romanian Health Insurance House (CNAS) has approved a new method of calculating reimbursement for partially reimbursed prescription-only drugs, which could lead to patients paying on average 40% more for their medication, and the Czech government is preparing a number of healthcare reforms that could see patients pay almost US$900 million more for their medicines every year. There are widespread concerns that many patients will not be able to afford to spend more on pharmaceuticals and certain pieces of legislation have been deemed unconstitutional.
Highlights from the report
POLAND
In May 2011, President Komorowski signed a controversial Drug Reimbursement Act into law, which is designed to curb the growth of drug reimbursement expenditure. The measures in the Act, which are to take effect from January 2012, include limiting drug reimbursement expenditure to 17% of total public healthcare spending, forcing pharmaceutical companies to cover half of any drug reimbursement overspending, applying fixed retail prices to reimbursed medicines, introducing fixed margins for wholesalers and requiring certain physicians and wholesalers to sign contracts with the NFZ, agreeing to prescribe and sell medicines at the official, fixed price. There are concerns that the elderly and those on low incomes will not be able to afford the new official prices and the Office of Competition and Consumer Protection has stated that fixed prices and margins on reimbursed drugs contravene free market principles.
ROMANIA
The Romanian pharmaceutical market will be the fourth largest in Central & Eastern Europe by 2016. It is expected to expand at a moderate CAGR between 2011 and 2016, although growth may be affected by slow economic recovery. Imports constitute a large proportion of the market. The expansion of the Romanian pharmaceutical market is largely driven by import growth; the value of imports increased by a double-digit CAGR between 2006 and 2010. Whilst the large population creates demand for pharmaceuticals, the low GDP per capita means that patients are unlikely to be able to afford the more expensive drugs and will settle for the cheaper alternatives.
RUSSIA
The presence of foreign manufacturers is increasing in Russia. A number of agreements have been made in 2011 between domestic and foreign companies that will benefit the Russian pharmaceutical market. These include a joint venture between India's Aurobindo Pharma and Russia's OJSC Diod; a licensing agreement between Norgine and Nycomed that gives the latter exclusive rights to commercialise MoviPrep in Russia; investment by Rusnano, Russia's government investment company, in Cleveland BioLabs' new subsidiary, Panacela Labs, which will develop a portfolio of new preclinical drug candidates in Russia; Pfizer and ChemRar High Technology Centre signing a memorandum of understanding to explore a collaboration focused on the research, development and commercialisation of innovative drugs in Russia; and the launching of Pro Bono Bio as a new international pharmaceutical company as a result of a three-year Anglo/Russian project.
UKRAINE
In June 2011, the Cabinet of Ministers adopted the state target scientific-technical programme for the development of new technologies to create domestic pharmaceuticals, which is designed to meet the human and veterinary medicinal needs of 2011-2015. State funding will account for almost half of the budget for the programme. A quarter of state funding will be used for the research & development of molecular and cellular technologies for creating biologically active substances. Investment funds will be used primarily to purchase modern equipment for the production of innovative medicinal substances, including immunological agents, vaccines and recombinant proteins.
THESE REPORTS ANALYSE THE ISSUES
The The Outlook for Pharmaceuticals in Central & Eastern Europe is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series. Table of Contents
BULGARIA
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- Local Manufacturers
- Actavis (formerly Balkanpharma)
- Bul Bio - National Centre of Infectious & Parasitic Diseases (BB-NCIPD)
- Sopharma
- Unipharm
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Clinical Trials
- Post-Market Surveillance
- GMP
- Advertising
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Actavis (Higia AD)
- Commercial League
- Kaliman RT
- Phoenix-Libra
- Sopharma
- Sting
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- HIV/AIDS
- Healthcare System
- Health Insurance
- User Fees
- National Health Strategy 2008-2013
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Bulgarian Pharmaceutical Market, 2009
- Bulgarian Pharmaceutical Market by Source, 2001-2005 (US$)
- Drug Consumption, 2001-2005 (Packs)
- Top-Ten Drugs by Volume, 2005
- Top-Ten Drugs by Value, 2005
- Top-Ten Domestically Produced Drugs by Volume, 2005
- Top-Ten Domestically Produced Drugs by Value, 2005
- Top-Ten Imported Drugs by Volume, 2005
- Top-Ten Imported Drugs by Value, 2005
- Leading ATC Groups by Volume, 2005
- Leading ATC Groups by Value, 2005
- Market Projections, 2009-2014
- SWOT Analysis of the Bulgarian Pharmaceutical Market, 2009
- Espicom Analysis of the Bulgarian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Sales of Locally-Produced Pharmaceuticals, 2001-2005
- Leading Domestic Producers by Value, 2005
- Members of BGPharmA, 2009
- Members of ARPharM, 2009
- Sopharma Financial Data, 1999-2007 (Thousand Leva)
- Exports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- Pharmaceutical Retailers, 2000-2006
- Summary of Demographic Data, 2007
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2007
- Hospital Bed Projections, 2009-2014
- Hospital Activity Trends, 2000-2006
- Projected Number of Physicians, 2009-2014
List of Charts
- Bulgarian Pharmaceutical Market, 2001-2005 (US$)
- Radar Graph of the Bulgarian Healthcare System
- Number of Reimbursed Drugs, 2000-2005
- Leading Distributors, 2005 (%)
CROATIA
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Croatian Chamber of Pharmacists
- Pharmaceutical Registration
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Notifiable Diseases
- HIV/AIDS
- Healthcare System
- Sustainable Health System Project
- National Health Strategy 2006-2011
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Healthcare Organisations
- Trade Associations/Organisations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Croatia Pharmaceutical Market, 2009
- Projected Pharmaceutical Market, 2009-2014
- Espicom Analysis of the Croatia Healthcare Sector
- SWOT Analysis of the Croatia Pharmaceutical Market
- Imports of Pharmaceuticals, 2003-2007 (US$000s)
- Import Trends (US$000s)
- Leading Suppliers, 2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Retail Medicaments, 2007 (US$000s)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends (US$000s)
- Leading Destinations, 2007 (US$000s)
- Leading Destinations of Raw Materials, 2007 (US$000s)
- Leading Destinations of Medicaments, 2007 (US$000s)
- Summary of Demographic Data, 2006-2008
- Projected Population, 2009-2014
- Projected Healthcare Expenditure, 2009
- Spending under the Health Insurance System, 2002-2006 (HRK Millions)
- Hospital Inpatient Activity, 1997-2007
- Healthcare Personnel, 2001-2007
CZECH REPUBLIC
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- Local Manufacturers
- Farmak
- Glenmark Pharmaceuticals (Medicamenta)
- ICN Czech Republic (VUAB)
- IVAX CR
- Pliva-Lachema
- Spofa
- Zentiva
- Financial Results
- Exports
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- New EU Rules
- Pharmaceutical Registration/Drug Approval Process
- Clinical trials
- Post marketing surveillance
- Advertising
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- Diabetes
- HIV/AIDS
- Healthcare System
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Czech Pharmaceutical Market, 2009
- Distributed Medicinal Products, 1995-2006
- Distributed Medicinal Products by ATC, 2006
- Market Projections, 2009-2014
- SWOT Analysis of the Czech Pharmaceutical Market, 2009
- Espicom Analysis of the Czech Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- API Manufacturers with GMP Certificates, January 2009
- Registered Pharmaceutical Manufacturers, January 2009
- AIFP Members, 2009
- CAFF Members, 2009
- Zentiva: Top Brands, 2007 (CZK millions)
- Zentiva Financial Results, 2000-2008
- Pharmaceutical Sales by Region, 2006-2007 (CZK millions)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- SUKL Drug Registration Activity, 2000-2007
- Pharmacies, 1999-2006
- Summary of Demographic Data, 2007/8
- Projected Population, 2009-2014
- Healthcare Expenditure, 2007
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2007
- Hospital Bed Projections, 2009-2014
- Hospital Activity Trends, 1998-2007
- Projected Number of Physicians, 2009-2014
List of Charts
- Distributed Medicinal Products by ATC, 2006 (CZK billion)
- Radar Graph of the Czech Healthcare System
HUNGARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Trade Associations
- Domestic Producers
- Biogal
- Chinoin
- Egis
- Gedeon Richter
- Human
- ICN Magyarorszag (Alkaloida)
- Keri Pharma
- Pharmavit
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- EU Regulatory Reforms
- Centralised procedure
- Mutual recognition procedure
- Pharmaceutical Registration
- Advertising
- Pricing & Reimbursement
- Decree 17/2007
- Price freezing and the Pharma Economic Act
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Distributors
- Hungaropharma
- Medimpex
- Pharmafontana
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- HIV/AIDS
- Healthcare System
- National Health Fund Administration
- Local Government
- Private Healthcare
- Healthcare Reform
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Healthcare Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Hungarian Pharmaceutical Market, 2009
- Per Capita Medicine Turnover by Area, 2006
- Market Projections, 2009-2014
- SWOT Analysis of the Hungarian Pharmaceutical Market, 2009
- Espicom Analysis of the Hungarian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Hungarian Pharmaceutical Production, 1990-2005 (HUF billions)
- Egis ANDA Approvals, 2002-2005
- Human Pharmaceuticals by Therapeutic Area, 2001-2005 (HUF millions)
- Leading Products by Turnover, 2007/8
- Egis Financial Results, 2002-2008 (HUF millions)
- Exports by Key Market, 2006-08 (US$000s)
- Gedeon Richter, Main Licensing Partners, 2008
- Product Sales by Therapeutic Group, 2002-2008 (%)
- Gedeon Richter, Top Ten Products, 2007-2008 (HUF millions)
- Gedeon Richter ANDA Approvals, 2002-2008
- Gedeon Richter Financial Results, 2001-2008 (HUF millions)
- Gedeon Richter, Top Ten Products in Hungary, 2007-2008 (HUF millions)
- Gedeon Richter Sales by Region, 2003-2008 (HUF millions)
- Gedeon Richter Top Ten Export Markets, 2007-2008 (US$ millions)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- Marketing Authorisation Fees, 2009
- Pharmacies, 1997-2006
- Summary of Demographic Data, 2006 & 2008
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2006
- Hospital Bed Projections, 2009-2014
- Projected Number of Physicians, 2009-2014
List of Charts
- Radar Graph of the Hungarian Healthcare System
- Gedeon Richter Products by Therapeutic Groups, 2008 (%)
- Gedeon Richter Key Markets Breakdown, 2008 (%)
POLAND
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Structural changes
- Biotechnology Industry
- Trade Associations
- Local Manufacturers
- Adamed Ltd.
- Bioton S.A.
- Jelfa SA
- Lek Polska
- Molteni Farmaceutici Polska
- Pliva Krakow
- Polfa Grodzisk
- Polfa Kutno
- Polfa Lodz
- Polfa Lublin
- Polfa Pabianice
- Polfa Rzeszow
- Polfa Tarchomin
- Polfa Warzsawa
- Polpharma
- Multinational Manufacturers
- Eli Lilly
- GlaxoSmithKline Poznan
- Nycomed (formerly Altana Pharma and Polfa Lyszkowice)
- Sanofi-Aventis
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Advertising
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- ACP Pharma (formally ORFE)
- Cefarm
- Phoenix Pharma Polska
- Polska Grupa Farmaceutyczna (PGF)
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Disease
- Incidence of Non-Communicable Disease
- HIV/AIDS
- National Programme for Combating AIDS and Preventing HIV Infections
for the Years 2007-2011
- Healthcare System
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Polish Pharmaceutical Market, 2009
- Market Projections, 2009-2014
- SWOT Analysis of the Polish Pharmaceutical Market, 2009
- Espicom Analysis of the Polish Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Parallel Imports
- Polfa Group Since Privatisation
- Bioton S.A. Financial Results, 2005-2007 (000s)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- Pharmacies and Pharmaceutical Outlets, 1995-2007
- Summary of Demographic Data, 2006/7
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2006
- Hospital Bed Projections, 2009-2014
- General Hospital Activity by Speciality, 1994-2001
- Projected Number of Physicians, 2009-2014
List of Charts
- Radar Graph of the Polish Healthcare System
ROMANIA
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- Local Manufacturers
- Actavis Romania (formerly Sindan)
- Antibiotice
- Gedeon Richter Romania
- GlaxoSmithKline (Europharm)
- Lek PharmaTech
- Terapia Ranbaxy
- Zentiva (formerly Sicomed)
- Exports
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Pharmaceutical Registration
- Clinical Trials
- Post-Marketing Surveillance
- Advertising
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- HIV/AIDS
- Healthcare System
- New Rules on Prescribing by Brand
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary Key Data Projections, 2009-2014
- Summary of the Romanian Pharmaceutical Market, 2009
- Hospital and Retail Pharmacy Sales, Q3 2005-Q2 2006 (million euros)
- Prescription Drugs and OTC Market, Q3 2005-Q2 2006 (million euros)
- Market Projections, 2008-2013
- SWOT Analysis of the Romanian Pharmaceutical Market, 2009
- Espicom Analysis of the Romanian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Antibiotice Financial Results, 2002-2007 (RON000s)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- NMA Authorisation Activity, 2007
- Pharmacies & Pharmaceutical Storehouses, 1999-2006 (000s)
- Summary of Demographic Data, 2005-2008
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2005/2006
- Hospital Bed Projections, 2009-2014
- Projected Number of Physicians, 2009-2014
List of Charts
- Radar Graph of the Romanian Healthcare System
- Applications for Marketing Authorisation/Renewal, 2004-2007
RUSSIA
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Pharmacy Market
- Hospital Market
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Government Programme for the Development of the Pharmaceutical Industry
- Trade Associations
- Local Manufacturers
- Akrikhin
- Bryntsalov A
- JSC Farmacon
- KRKA
- Makiz
- Nizhpharm
- Otechestvennye Lekarstva (Erka Farm)
- Pharmstandard
- Veropharm
- Yugrafarm
- Multinational Manufacturers
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Pharmaceutical Registration
- Clinical Trials
- Import Regulations
- Advertising
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Protek
- Shreya Corporation
- SIA International
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Disease
- Incidence of Non-Communicable Disease
- HIV/AIDS
- Healthcare System
- Concept for the Development of the Healthcare Sector until 2020
- National ‘Health’ Project
- World Bank Projects
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Regional Health Authorities
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Russian Pharmaceutical Market, 2009
- Top Ten ATC Groups by Pharmacy Sales Value, 2006-2008 (%)
- Top Ten ATC Groups by Hospital Purchases, 2006-2008 (%)
- Top Ten Manufacturers by DLO Value, 2007-2008 (%)
- Top Ten ATC Groups by DLO Value, 2007-2008 (%)
- Top Ten Trade Names by DLO Value, 2007-2008 (%)
- Top Ten Generic Drugs in the Retail Sector, Q1-Q2 2007
- Top Ten Generic Companies, Q1-Q2 2007
- Top Ten Manufacturers, Trade Names and ATG Groups in the OTC Market, 2008
- Market Projections, 2009-2014
- SWOT Analysis of the Russian Pharmaceutical Market, 2008
- Espicom Analysis of the Russian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Top Ten Domestic Producers, 2007 (US$ millions)
- Nizhpharm Sales, 1999-2003
- Pharmstandard Production by Facility, 2008
- Pharmstandard Production by Facility, 2008
- Pharmstandard Financial Results, 2004-2008 (R Millions)
- Pharmstandard Pharmaceutical Sales, 2007-2008
- Pharmstandard Top 10 OTCs, 2007-2008
- Top Pharmaceutical Companies by Sales, 2004-2006 (%)
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- Summary Demographic Data, 2007-2008
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals and Beds, 2000-2007
- Hospital Bed Projections, 2009-2014
List of Charts
- Radar Graph of the Russian Healthcare System
SERBIA
- PHARMACEUTICAL MARKET
- Current Size
- Projections
- Outlook
- Market Structure
- Domestic Production
- Imports
- Exports
- Research & Development
- Market Developments
- Private Medical Insurance
- World Bank Loan
- National Strategy against Malignant Diseases to Reduce Cancer Rate
- MoH Issues Reminder on Rules for Advertising Medicines
- Serbia and Montenegro to Co-operate in Field of Healthcare
- Co-operation between Serbian and Hungarian Health Ministries to be
Strengthened
- Opening of Preventive Healthcare Centres
- MoH Launches Campaign to Inform on Patients' Rights
- Medicines and Medical Equipment Agency Receives ISO 9001 Certificate
- EU Financing for Blood Transfusion Centres
- Serbia and Bulgaria Sign Co-operation Agreement
- World Bank Health Project, 2003-08
- KEY NATIONAL DATA PROJECTIONS
List of Tables
- Summary of the Serbian Pharmaceutical Market in 2008
- Projected Pharmaceutical Market, 2008-2013
- SWOT Analysis of the Serbian Pharmaceutical Market
- Espicom Analysis of the Serbian Health Sector
- Structure of the Pharmaceutical Industry, 2005
- Imports of Pharmaceuticals by Category, 2002-2006 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2006 (US$000s)
- Leading Suppliers of Medicaments, 2006 (US$000s)
- Exports of Pharmaceuticals, 2002-2006 (US$000s)
- Export Trends
- Leading Destinations, 2006 (US$000s)
- Key Data, 2008-2013
List of Figures
- Radar Graph of the Serbian Healthcare System
SLOVAKIA
- Pharmaceutical Market
- Size
- Market Structure
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Local Manufacturers
- Biotika
- Imuna Pharm
- Hoechst Biotika
- Zentiva
- Multinational Manufacturers
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Pharmaceutical Testing & Clinical Trials
- Post-Market Surveillance
- Advertising
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Disease
- Incidence of Non-Communicable Disease
- HIV/AIDS
- Healthcare System
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary Key Data Projections, 2009-2014
- Summary of the Slovakian Pharmaceutical Market in 2009
- Pharmaceutical Consumption, 2002-2007
- Projected Generic Market, 2007-2014 (US$ millions)
- OTC Market by Volume, 2000-2006
- Market Projections, 2009-2014
- SWOT Analysis of the Slovakian Pharmaceutical Market
- Espicom Analysis of the Slovakian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Registered Pharmaceutical Manufacturers
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends, 2006-2007 (US$000s)
- Leading Destinations, 2007 (US$000s)
- The Positive List, 2007
- ADL Members, 2009
- Summary Demographic Data, 2008
- Projected Population, 2009-2014
- Expenditure on Medicinal Products by Health Insurance Company, 2007
- Projected Health Expenditure, 2009-2014
- Hospitals and Beds, 2004-07
- Hospital Bed Projections, 2009-2014
- Inpatient Activity, 2001-2007
- Projected Number of Physicians, 2009-2014
List of Charts
- Pharmaceutical Expenditure, 2002-2007 (SKK millions)
- Radar Graph of the Slovakian Healthcare System
- Pharmacies, 1998-2007
SLOVENIA
- PHARMACEUTICAL MARKET
- Current Size
- Projections
- Outlook
- Market Structure
- Generics
- OTC Products
- Domestic Production
- Domestic Producers
- Imports
- Exports
- Market Developments
- KEY NATIONAL DATA PROJECTIONS
List of Tables
- Summary of the Slovenian Pharmaceutical Market in 2009
- Projected Pharmaceutical Market, 2009-2014
- SWOT Analysis of the Slovenian Pharmaceutical Market
- Espicom Analysis of the Slovenian Health Sector
- Drug Consumption and Expenditure, 2001 & 2005
- Number of Prescriptions Issued by ATC Classification, 2004
- OTC Market, 2001-2002 (million euros)
- Krka Financial Results, 1998-2006 (SIT millions)
- Lek Financial Results, 1997-2004 (SIT millions)
- Imports of Pharmaceuticals by Category, 2004-2008 (US$000s)
- Import Trends (US$000s)
- Leading Suppliers of Raw Materials, 2008 (US$000s)
- Leading Suppliers of Medicaments, 2008 (US$000s)
- Exports of Pharmaceuticals, 2004-2008 (US$000s)
- Export Trends (US$000s)
- Leading Destinations, 2008 (US$000s)
- Leading Destinations of Retail Medicaments, 2008 (US$000s)
- Key Data, 2009-2014
List of Figures
- Radar Graph of the Slovenian Healthcare System
UKRAINE
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Pharmacy Market
- Hospital Market
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Local Manufacturers
- Arterium
- Borschagovsky Chemical & Pharmaceutical Plant
- Darnitsa
- Farmak
- Exports
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Advertising
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Non-communicable Diseases
- Chernobyl Nuclear Disaster
- HIV/AIDS
- Healthcare System
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Ukrainian Pharmaceutical Market, 2009
- Top Ten Products by Pharmacy Sales Value, 2007-2008 (%)
- Top Ten Manufacturers by Pharmacy Sales Value, 2007-2008 (%)
- Top Ten ATC Groups by Pharmacy Sales Value, 2007-2008 (%)
- Top Ten Products by Hospital Purchases, 2007-2008 (%)
- Top Ten Manufacturers by Hospital Purchases, 2007-2008 (%)
- Top Ten ATC Groups by Hospital Sales Value, 2007-2008 (%)
- Market Structure, 2005-August 2008 (% of Total)
- Summary of the OTC Market, 2007
- OTC Market by Drug Prices, 2007 (%)
- Top 10 Manufacturers, Trade Names & ATC Groups by Pharmacy Sales, 2007
- Market Projections, 2009-2014
- SWOT Analysis of the Ukrainian Pharmaceutical Market, 2009
- Espicom Analysis of the Ukrainian Health Sector, 2009
- Imports of Pharmaceuticals by Category, 2002-2006 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2006 (US$000s)
- Leading Suppliers of Medicaments, 2006 (US$000s)
- Top 30 Pharmaceutical Companies by Value, August 2008
- Exports of Pharmaceuticals, 2002-2006 (US$000s)
- Export Trends
- Leading Destinations, 2006 (US$000s)
- Marketing Authorisations by Pharmaceutical Form, September 2007
- Top 10 Distributors/Importers, 2007-2008 (%)
- Top 10 Pharmacy Chains, 2007
- Summary of Demographic Data, 2007/08
- Projected Population, 2009-2014
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2005/2006
- Hospital Bed Projections, 2009-2014
- Hospital Activity by Specialty, 2001
- Projected Number of Physicians, 2009-2014
List of Charts
- Radar Graph of the Ukrainian Healthcare System
- Market Shares of Domestic & Foreign Companies, 2003-2005 (%)
|
 |
